Highlights
• Seven brokerages maintain a consensus “Buy” rating on Vitalhub shares
• Average 12-month price target stands at CAD 13.25
• Analysts from Scotiabank and Raymond James rate VHI as “Outperform”

Vitalhub Corp. (TSE:VHI) has received consistent support from analysts, with seven brokerages currently covering the stock and issuing a consensus recommendation of “Buy”. The research coverage reflects ongoing confidence in the company’s performance outlook, particularly in the healthcare software segment where it operates. Out of the seven analysts, six have rated the stock a “Buy” and one has assigned a “Strong Buy” rating.

The average 12-month price target for Vitalhub stands at CAD 13.25, implying potential upside from recent trading levels. Analysts have issued updated targets in the past two months, indicating continued review of Vitalhub’s financials and strategic developments.

On June 20th, Scotiabank raised its price target on the stock from CAD 14.00 to CAD 14.50 and maintained an “Outperform” rating, suggesting a positive reassessment of the company's growth prospects. Similarly, Raymond James also updated its view on June 20th, lifting its target from CAD 13.50 to CAD 14.00 while maintaining an “Outperform” rating. These revisions reflect analyst expectations for operational execution and potential revenue visibility in upcoming quarters.

Meanwhile, National Bank Financial upgraded its rating to “Strong Buy” earlier on June 9th, indicating elevated conviction in the stock’s valuation relative to growth expectations. National Bankshares followed with a CAD 14.00 price target and an “Outperform” rating on June 10th.

Vitalhub, which focuses on developing software solutions for health and human services providers, has attracted attention for its ability to secure institutional clients and scale its platform through acquisitions and recurring revenues. However, analysts’ confidence appears grounded more in projected earnings consistency and strategic market positioning than short-term catalysts.